You are here

IGF OT IGF MULTIPLEXED HIGH CONTENT ASSAY FOR TOXICITY MECHANISMS AND PHENOTYPES IN LIVE IPSC DERIVED CARDIAC CELLS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 271201600006C-0-0-0
Agency Tracking Number: N43DA160006
Amount: $229,893.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDA
Solicitation Number: N/A
Timeline
Solicitation Year: 2016
Award Year: 2016
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3534 24TH ST
SAN FRANCISCO, CA 94110-3606
United States
DUNS: 078744267
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 AMANDA GRAMLICH
 (415) 269-2956
 maryludlam@gmail.com
Business Contact
 AMANDA GRAMLICH
Phone: (415) 269-2956
Email: maryludlam@gmail.com
Research Institution
N/A
Abstract

Toxicological assessments rely on low throughput costly animal studies that deliver minimal insights into compound toxicity mechanisms Induced pluripotent stem cells iPSCs are positioned to transform the evaluation of toxic compounds by enabling predictive physiologically relevant model systems compatible with high throughput screening Combining these iPSC benefits with high content screening approaches that enable diverse mechanistic and phenotypic readouts in living cells will deliver important new predictive toxicity evaluation capabilities The goal of this contract is to demonstrate the feasibility and benefits of this approach by delivering a novel multiplexed well plate format high content assay with distinct mechanistic stress response readouts and phenotypic organelle based reporters in iPSC derived cardiomyocytes Cairn will validate the assays response to tool compounds known to cause cardiotoxicity and demonstrate its compatibility with high throughput screening of at least samples day

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government